Subscribe to our Newsletters !!
There is one fact about life on Earth we cannot es
The pharmaceutical, laboratory, and analytical ind
The Nobel Prize in Physiology or Medicine awarded
India is one of the largest centers of global phar
By the end of 2025, the pharma, laboratory, and an
Tofu has been a favorite food for vegetarians and
Dear Readers, Welcome to the latest issue of Micro
The last several years have seen the integration of nanotechnology and microfluidics become one of the most promising areas for the advanced manufacturing of nanocarriers for use in drug and vaccine delivery.
This integration is beginning to drive development throughout the healthcare and biopharma sectors by consolidating microfluidic systems as a means to conduct both translational research and produce goods for large-scale industry.
The biopharmaceutical industry has experienced a shift in paradigms due to the development of systems that allow effective, targeted, and controlled delivery of therapeutic agents. Sophisticated systems such as lipid nanoparticles (LNPs), liposomes, and other polymeric nanoparticles have become staples of contemporary drug delivery and gene therapy. The clinical achievement of RNA-based vaccines, as well as the swift advancement in cell and gene therapies, has highlighted the imperative to have a manufacturing platform that is robust, reproducible, and scalable for the production of nanoformulations.
Figure 1. A schematic illustration of nanoparticle synthesis using a microfluidic chip.
Figure 2. Schematic representation of various types of nanoparticles commonly used for drug encapsulation and nanoformulation. A. lipid nanoparticles, B. emulsions /double emulsions, C. polymeric nanoparticles, D. liposomes / hybrid nanoparticles
The branch of science known as microfluidics involves the study of how to control the flow of liquids through systems of channels that are measured in micrometers. Microfluidics parameters modifiable include to what extent fluids are mixed and the rate at which they flow.
These parameters can be adjusted to achieve the desired values of size, polydispersity, and encapsulation efficiency of nanoparticles. Among the various other applications, microfluidics can be utilized to manufacture various kinds of nanomaterials such as liposomes, lipid nanoparticles, and other polymeric nanoparticles in the bioscience industry.
Therefore, given how many kinds of nanomaterials can be fabricated, microfluidics can be regarded as a “factory of the future” for the quickly evolving nanomedicine field, and can be viewed as a general manufacturing platform for nanoparticles and nanoformulations.
The Control and Engineering Benefits of Microfluidic Systems Microfluidic systems are also beginning to be preferred in the manufacturing field because they offer less control over the size and uniformity of nanoparticles produced as compared to bulk processes. Better size uniformity in nanoparticles produced can be manufactured to a desired size better as compared to bulk. The more innovative systems of microfluidics allows for better control.
Designing chips that better integrates systems that facilitate resource management, monitoring, and control in real-time to optimize and enhance the consistency of production while reducing the amount of materials, thereby lessening the waste generated provides greater utility. These are the reasons that microfluidics is better than other systems for producing next-generation nanomedicines.
Figure 3. Schematic representation of the key advantages of microfluidic systems in nanoparticle manufacturing.
Nanoparticle-based therapeutics are becoming more popular. To ensure these and future therapeutics are available, microfluidic technology, capable of full automation and seamless integration with industrial systems, will need to be developed. Amar Biosystems Pvt. Ltd. has become one of the first companies attempting to develop and sell fully automated microfluidic systems with their Nanomake-L product. Along with the Make-in-India initiative, Amar Biosystems will be able to manufacture and distribute systems that will help the developing biopharma industry.
Besides being fully automated, the Nanomake-L has a variety of features that can further improve customer satisfaction, such as a reusable chip, washable guide tubing, and flexible sample collection options with a wide range of operating flow rates and distributable sample collection.
As the discipline develops, the microfluidics industry will bring more than just incremental change. With the coupling of the remaining microfluidics related disciplines, the engineering, biology, and materials science integration will provide the fully developed microfluidics industry with a diverse portfolio of solutions.
